Company intelligence / Profile preview

Advanced Viral Research Corp.

Yonkers, New York, United Statesfiercebiotech.com ↗

Ownership: Private
Employees: ~75
Development stage: Phase 2

Overview

The company suspended operations in January 2009 due to inability to secure financing. Prior to that, it was developing compounds AVR118 and AVR123 for treating cachexia (wasting syndrome) and wound healing.

Therapeutic areas: OncologyImmunologyInfectious DiseasesHematology
Modalities: Small moleculesPeptide-nucleic acid complexesRecombinant polypeptides
Industry: Biotech

Drug pipeline

2 assets

EOM613

Phase 2

Indications: Cancer cachexia, Infectious disease, COVID-19, Rheumatoid arthritis

1 more asset in the full pipeline.

Request access →

Partnerships

Don Byme organization (Mexico)

Beyond the preview

Go deeper on Advanced Viral Research Corp..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Advanced Viral Research Corp..

Explore the full profile